Nucleus RadioPharma announced the development of two new facilities totalling over 100,000 square feet in Mesa, Arizona and Springhouse, Pennsylvania. These first-of-a-kind facilities will house ...

The healthcare industry stands apart in its complexity and stakes—where every decision, every action can be a matter of life ...

Nuclidium announced that the first patient has been successfully imaged in a phase 1 clinical trial evaluating the company’s radiotracer candidate as a safe and accurate diagnostic and disease-staging ...

EMA committee recommends extended authorization for BeiGene’s Tevimbra to treat gastric or gastroesophageal junction cancer & ESCC: San Mateo, California Wednesday, October 23, ...

US FDA clears HELP Therapeutics’ IND application for universal iPSC-derived HiCM-188 cell therapy to treat end-stage heart failure: Nanjing, China Wednesday, October 23, 2024, 1 ...

Samsung Biologics inks largest manufacturing deal with Asia-based pharma company: Incheon, S. Korea Wednesday, October 23, 2024, 09:00 Hrs [IST] Samsung Biologics, a global contra ...

India and Germany to advance translational research in neurosciences with focus on pain management: Nandita Vijayasimha, Bengaluru Wednesday, October 23, 2024, 08:00 Hrs [IST] Ind ...

Anticipating notification, TN IPGA starts training programme for drug inspector and medical devices officer exams: Peethaambaran Kunnathoor, Chennai Wednesday, October 23, 2024, 0 ...

The Pharmacy Council of India (PCI) has informed all State Pharmacy Councils that the council has initiated continuing education programmes and skill development programmes to improve the skill sets ...

DTAB recommends amendment of Rule 64 related to qualification of competent person for wholesale license: Gireesh Babu, New Delhi Wednesday, October 23, 2024, 08:00 Hrs [IST] The D ...

Justice D.Y. Chandrachud has stressed on intersection of law, ethics and medical innovation in gene therapy for treatment of rare diseases. Speaking after inaugurating a conference on ‘Gene Therapy ...

Angelini Pharma, Cureverse enter exclusive global option agreement to develop & commercialize innovative brain health asset, CV-01: Rome, Italy Tuesday, October 22, 2024, 17:00 Hr ...